Status: Not yet recruiting
Evaluation of the Safety and Efficacy of XoGlo Pro, a Placental Mesenchymal Stem Cell-derived Extracellular Vesicles in Treating COVID-19 Symptoms
Investigational New Drug trial investigating safety as primary endpoint and clinical efficacy as secondary endpoint of placental, mesenchymal stem cell-derived extracellular vesicles for the treatment of COVID-19 symptoms in adults with mild to moderate illness.
Participants needed: 64
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Kimera Labs Inc.Updated: Jun 24, 2026
Eligibility criteria
Adult subjects of either gender aged more than 18 years. [+5]
Subjects who test positive for SARS-CoV-2 using a virologic test but have no sym... [+9]